Nkarta, Inc.
Nkarta, Inc. (Nasdaq: NKTX) is a clinical-stage biopharmaceutical company developing allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. Its lead product candidate, NKX019, is a donor-derived CAR NK cell therapy designed to target CD19-positive B cells and is being studied for autoimmune diseases,… From the company’s description.
In fiscal 2025, Nkarta, Inc. reported a net loss of $104.08M. Operations used $88.70M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Nkarta, Inc. does
In the company’s own words
Nkarta, Inc. (Nasdaq: NKTX) is a clinical-stage biopharmaceutical company developing allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. Its lead product candidate, NKX019, is a donor-derived CAR NK cell therapy designed to target CD19-positive B cells and is being studied for autoimmune diseases, including lupus nephritis, primary membranous nephropathy, systemic sclerosis, myositis, ANCA-associated vasculitis, systemic lupus erythematosus and myasthenia gravis. The company’s proprietary platform is designed to expand and engineer NK cells, support their persistence, and enable cryopreservation for use as a frozen, ready-to-administer product. Nkarta previously studied NKX019 in blood cancers and its NKG2D-targeted candidate NKX101 in hematologic malignancies; it has deprioritized those oncology programs to focus on autoimmune diseases. The company operates two cGMP manufacturing facilities in South San Francisco, California, and reports no operating segments. Its website is www.nkartatx.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- SOUTH SAN FRANCISCO, CA
- Fiscal year end
- December
- CIK
- 1787400
- SIC
- 2834
Financial performance, year by year
Fiscal 2020–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Nkarta, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Nkarta, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Nkarta, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Nkarta, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Nkarta, Inc.'s last four quarterly filings that the numbers alone won't show?”